

Haematologica
HAEMATOL/2018/211904
Version 4

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

Anna Vidal-Crespo, Alba Matas-Céspedes, Vanina Rodriguez, Cédric Rossi, Juan G. Valero, Neus Serrat, Alejandra Sanjuan Pla, Pablo Menéndez, Gaël Roué, Armando López-Guillermo, Eva Giné, Elías Campo, Dolores Colomer, Christine Bezombes, Jeroen Lammerts van Bueren, Christopher Chiu, Parul Doshi, and Patricia Pérez-Galán

Disclosures: P.Pérez-Galán received funding from Genmab and Janssen pharmaceuticals C. Chiu is a Janssen employer P. Doshi was a Janssen employer J Lammerts van Bueren was a Genmab employer

Contributions: 1. Conception and design of the work 2. Experimental design 3. Acquisition/collection of data 4. Analysis or interpretation of data 5. Manuscript writing and editing AVC: 2,3,4 and 5 AMC: 2,3,4 and 5 VR: 2 and 3 CR: 2,3 and 4 JGV:3 and 4 NS:3 and 4 ASP:3 PM: 5 GR: 5 ALG: 5 EG: 5 EC: 5 DC: 5 CB: 2 and 5 JLvB: 1, 2 and 5 CC: 1, 2 and 5 PD: 1, 2 and 5 PPG: 1,2,3,4 and 5